Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins

Phlebology

Volumn 23, Issue 1, 2008, Pages 15-20

  Yasim, A ^a   Kilinc M ^a   Aral, M ^a   Oksuz, H ^a   Kabalci, M ^a   Eroglu, E ^a   Imrek, S ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

Inflammation; Varicose veins; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; INTERLEUKIN 12; INTERLEUKIN 6; MALONALDEHYDE; NITRIC OXIDE; PLASMA PROTEIN; PROCOAGULANT; PROSTACYCLIN; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASODILATOR AGENT; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM LESION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; VARICOSIS; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; UPREGULATION; VASCULAR ENDOTHELIUM; VEIN INSUFFICIENCY;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-12; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN S; UP-REGULATION; VARICOSE VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS; VENOUS INSUFFICIENCY; VON WILLEBRAND FACTOR;

EID: 41949139088     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2007.007014     Document Type: Article

References (22)

1. Rizzi A, Quaglio D, Vasquez G, et al. Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg 1998;28:855-861
2. 1α in human (varicose) veins: influence of age, sex, and risk factors. Angiology 2003;54:317-324
3. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement. Circulation 2000;102:e126-63
4. Shireman PK, McCarthy WJ, Pearce WH, et al. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein. J Vasc Surg 1996;24:719-724
5. Golledge J, Quigley FG. Pathogenesis of varicose veins. Eur J Vasc Endovasc Surg 2003;25:319-324 (Pubitemid 36527629)
6. Howlader MH, Coleridge-Smith PD. Symptoms of chronic venous disease and associated with systemic inflammatory markers. J Vasc Surg 2003;38:950-954 (Pubitemid 37409627)
7. Glowinsky J, Glowinsky S. Generation of reactive oxygen metabolites by the varicose vein wall. Eur J Vasc Endovasc Surg 2002;23:550-555 (Pubitemid 41079408)
8. Yao JS. Venous disorders - reflections of the past three decades. J Vasc Surg 1997;26:727-735
9. Hollingsworth SJ, Tang CB, Dialynas M, et al. Varicose vein: loss of release of vascular endothelial growth factor and reduced plasma nitric oxide. Eur J Vasc Endovasc Surg 2001;22:551-556
10. Coleridge-Smith PD. Update of chronic venous insufficiency-induced inflammatory processes. Angiology 2001;52:S35-42 (Pubitemid 32777514)
11. Jacob MP, Cazaubon M, Scemama A, et al. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 2002;106:535-538
12. Hollingsworth SJ, Powell GL, Barker SGE, et al. Primary varicose veins: altered transcriptions of VEGF and its receptors (KDR, flt-1, soluble flt-1) with saphenofemoral junction incompetence. Eur J Vasc Endovasc Surg 2004;27:259-268
13. Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res 2000;47:426-435 (Pubitemid 30646065)
14. Clauss A. Gerinnungs physiologische Schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957;17:237-246
15. Flore R, Santoliquido A, Antonio DL, et al. Long saphenous vein stripping reduces local level of reactive oxygen metabolites in patients with varicose disease of the lower limbs. World J Surg 2003;27:473-475
16. Zamboni P, Izzo M, Tognazzo S, et al. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. Free Radic Biol Med 2006;40:1869-1873
17. Murphy MA, Joyce WP, Condron C, et al. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 2002;23:349-352
18. Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavanoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-338 (Pubitemid 29481457)
19. Howlader MH, Coleridge-Smith PD. Relationship of plasma vascular endothelial growth factor to CEAP clinical stage and symptoms in patient with chronic venous disease. Eur J Vasc Endovasc Surg 2004;27:89-93 (Pubitemid 38009000)
20. Bates DO, Hillman NJ, Pocock TM, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:529-530
21. Bertrand-Tiebault C, Ferrari L, Boutherin-Falson O, et al. Cytochromes p450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004;31:295-301
22. Boisseau M, Freyburger G, Busquet M, Bertrand M. Incidence of haemorheological abnormalities in microcirculatory disorders: contribution of Daflon 500 mg. Phlebology 1992;2(Suppl):17-21